基因组编辑市场规模、份额、成长分析、按技术、交付方式、按应用、按模式、按最终用途、按地区 - 行业预测，2024-2031 年

2022年全球基因组编辑市场规模为77亿美元，从2023年的89.9亿美元成长到2031年的311.5亿美元，复合年增长率预计将成长16.80%。

基因组编辑涉及透过切割、添加或删除序列来修改生物体的 DNA，以改变遗传特征。该技术旨在透过精确改变细胞基因组来赋予细胞特定的特性。世界各国政府正透过向公共机构、私人公司和学术机构提供资助和奖励，增加对 KEYWORD 研究的投资。这种不断增加的支持正在推动预测期内基因组编辑市场的积极成长。有几个因素促进了基因组编辑市场的扩张。其中包括癌症和遗传疾病盛行率的上升、对个人化医疗的日益偏好、研发成本的增加以及生物技术和製药行业的进步。私人和公共资金的激增、测序技术的快速进步以及基因组编辑技术的进步也是关键驱动因素。 CRISPR技术的采用以及各个生物技术领域对合成基因的需求不断增加，对该市场产生了重大影响。此外，市场竞争的加剧正在加速基因组编辑市场的成长。例如，Vertex Pharmaceuticals 于 2021 年 4 月与 CRISPR Therapeutics 达成 9 亿美元协议，开发和商业化针对 β 地中海贫血和镰状细胞疾病的 CRISPR-Cas9 基因编辑疗法，这证实了其动态性质。此类投资和倡议预计将进一步推动基因组编辑市场的成长。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 技术分析
• 价格分析
• 价值链分析
• 市场生态系统
• 贸易分析
• 供应链分析
• 案例研究分析
• 专利分析
• 客户和购买标准分析
• 监管环境
• 创新矩阵
• 主要投资分析
• 关键成功因素
• 竞争程度

基因组编辑市场：依技术分类

• 市场概况
• （CRISPR）/Cas9
• TALEN/MegaTALs
• ZFN
• Meganucleases
• 其他的

基因组编辑市场：依交付方式

• 市场概况
• Ex-vivo
• In-Vivo

基因组编辑市场：依应用分类

• 市场概况
• 基因工程
  • 细胞株工程
  • 动物基因工程
  • 植物基因工程
  • 其他的
• 临床应用
  • 诊断
  • 治疗开发

基因组编辑市场：按模式

• 市场概况
• 委託
• 公司内部

基因组编辑市场：依最终用途分类

• 市场概况
• 生物技术和製药公司
• 学术和政府研究机构
• 受託研究机构

基因组编辑市场规模：按地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Merck KGaA（Germany）
• Cibus Inc（US）
• Recombinetics（US）
• Sangamo Therapeutics（US）
• Editas Medicine（US）
• Precision BioSciences（US）
• CRISPR Therapeutics（Switzerland）
• Intellia Therapeutics, Inc（US）
• Caribou Biosciences, Inc.（US）
• Cellectis SA（France）
• AstraZeneca（UK）
• Takara Bio Inc.（Japan）
• Horizon Discovery Ltd.（Revvity, Inc.）（UK）
• Danaher Corporation（US）
• Transposagen Biopharmaceuticals, Inc.（US）
• Genscript Biotech Corp（China）
• New England Biolabs（US）
• OriGene Technologies, Inc.（US）
• bluebird bio, Inc（US）
• Lonza（Switzerland）
• Thermo Fisher Scientific, Inc.（US）

Global Genome Editing Market size was valued at USD 7.70 billion in 2022 and is poised to grow from USD 8.99 billion in 2023 to USD 31.15 billion by 2031, growing at a CAGR of 16.80% during the forecast period (2024-2031).

Genome editing involves modifying an organism's DNA by cutting and adding or removing sequences to alter its genetic traits. This technique aims to endow cells with specific characteristics by making precise changes to their genome. Governments globally are investing more in genome editing research by providing funding and awards to both public and private sectors, as well as academic institutions. This increased support is driving positive growth in the genome editing market during the forecast period. Several factors are contributing to the expansion of the genome editing market. These include the rising prevalence of cancer and genetic disorders, the growing preference for personalized medicine, increased research and development expenditures, and advancements in biotechnology and pharmaceutical industries. The surge in both private and public funding, rapid progress in sequencing technologies, and advancements in genome editing techniques are also key drivers. The market has been significantly influenced by the adoption of CRISPR technology and the growing demand for synthetic genes across various biotechnology fields. Additionally, heightened competition among market players is accelerating the growth of the genome editing market. For example, Vertex Pharmaceuticals' $900 million agreement with CRISPR Therapeutics in April 2021 to develop and commercialize CRISPR-Cas9 gene-edited therapies for beta-thalassemia and sickle cell disease underscores the sector's dynamic nature. Such investments and initiatives are expected to further propel the growth of the genome editing market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Genome Editing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Genome Editing Market Segmental Analysis

Global Genome Editing Market is segmented by Technology, Delivery Method, Application, Mode, End-use, and region. Based on Technology, the market is segmented into (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease, and Others. Based on Delivery Method, the market is segmented into Ex-vivo, and In-Vivo. Based on Application, the market is segmented into Genetic Engineering, and Clinical Applications. Based on Mode, the market is segmented into Contract, and In-house. Based on end use, the market is segmented into Biotechnology and pharmaceutical companies, Academic and government research institutes, and Contract research organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Genome Editing Market

In recent years, governments globally have significantly invested in genomics, which has greatly advanced the field of genome editing. This support has allowed both academic and governmental institutions to conduct extensive research into genome editing and engineering. For example, the Ministry of Innovation, Science, and Industry (Science) awarded a $15 million grant to Genome Canada to fund 11 genomic research projects focused on health, agriculture, and environmental applications. Additionally, provincial governments, businesses, and research partners are contributing a combined total of $29.7 million to these initiatives, including research into ovarian and cervical cancer. These substantial investments have led to a considerable increase in genomics research projects. The resulting advancements and innovations are expected to drive growth in the genome editing market throughout the forecast period. The increased funding and support from various government bodies are fostering a robust research environment, which is likely to accelerate the development of new genome editing technologies and applications.

Restraints in the Global Genome Editing Market

Off-target effects associated with CRISPR-Cas9 are a significant concern in genome editing. The Cas9 enzyme creates double-stranded breaks in DNA, and any unintended nuclease activity can lead to mutations in non-target genes, potentially triggering oncogenesis. CRISPR-Cas9 can tolerate one to three mismatches in its target sequence, which increases the risk of off-target activity. This unintended activity can occur at a high frequency, with up to 50% of mutations happening at sites other than the intended target. For example, CRISPR might inadvertently target tumor suppressor genes or activate oncogenes. These issues have led to challenges in clinical trials, causing some to be halted. Regulatory bodies are now calling for more research to enhance the safety and precision of CRISPR-Cas9 technology.

Market Trends of the Global Genome Editing Market

The COVID-19 pandemic has spurred significant investments from major pharmaceutical and biotechnology companies, as well as from key players in the genomic sector, into vaccine research and development. This surge in investment is driven by the heightened demand for vaccines and antiviral treatments, which has placed genome editing and engineering technologies at the forefront of the industry. As a result, these advancements are anticipated to be a major force propelling the growth of the genome editing market in the coming years. The increased focus on developing effective vaccines and therapies underscores the growing importance of genome editing technologies in addressing global health challenges.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Trade Analysis
• Supply chain Analysis
• Case study Analysis
• Patent Analysis
• Customer & Buying Criteria Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Genome Editing Market by Technology

• Market Overview
• (CRISPR)/Cas9
• TALENs/MegaTALs
• ZFN
• Meganuclease
• Others

Genome Editing Market by Delivery Method

• Market Overview
• Ex-vivo
• In-Vivo

Genome Editing Market by Application

• Market Overview
• Genetic Engineering
  • Cell Line Engineering
  • Animal Genetic Engineering
  • Plant Genetic Engineering
  • Others
• Clinical Applications
  • Diagnostics
  • Therapy Development

Genome Editing Market by Mode

• Market Overview
• Contract
• In-house

Genome Editing Market by End-use

• Market Overview
• Biotechnology and pharmaceutical companies
• Academic and government research institutes
• Contract research organizations

Genome Editing Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cibus Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recombinetics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Editas Medicine (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision BioSciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics, Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caribou Biosciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellectis S.A (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Discovery Ltd. (Revvity, Inc.) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transposagen Biopharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genscript Biotech Corp (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• New England Biolabs (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OriGene Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bluebird bio, Inc (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments